BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 12562237)

  • 41. Prognostic value of bcl-6, CD10 and CD38 immunoreactivity in stage I-II gastric lymphomas: identification of a subset of CD10+ large B-cell lymphomas with a favorable outcome.
    Ponzoni M; Ferreri AJ; Pruneri G; Pozzi B; Dell'Oro S; Pigni A; Pinotti G; Villa E; Freschi M; Viale G; Capella C
    Int J Cancer; 2003 Aug; 106(2):288-91. PubMed ID: 12800208
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
    Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
    Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
    Oh EJ; Yang WI; Cheong JW; Choi SE; Yoon SO
    Hum Pathol; 2014 Oct; 45(10):2043-50. PubMed ID: 25149548
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular heterogeneity of diffuse large B-cell lymphoma: implications for disease management and prognosis.
    Rossi D; Gaidano G
    Hematology; 2002 Aug; 7(4):239-52. PubMed ID: 14972786
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a marker of poor prognosis.
    Bodoor K; Matalka I; Hayajneh R; Haddad Y; Gharaibeh W
    Asian Pac J Cancer Prev; 2012; 13(7):3037-46. PubMed ID: 22994707
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinicopathological features of primary diffuse large B-cell lymphoma of the central nervous system - strong EZH2 expression implying diagnostic and therapeutic implication.
    Guo S; Bai Q; Rohr J; Wang Y; Liu Y; Zeng K; Yu K; Zhang X; Wang Z
    APMIS; 2016 Dec; 124(12):1054-1062. PubMed ID: 27807891
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.
    Bosch M; Akhter A; Chen BE; Mansoor A; Lebrun D; Good D; Crump M; Shepherd L; Scott DW; Stewart DA
    Haematologica; 2018 Feb; 103(2):288-296. PubMed ID: 29097500
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
    Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
    PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas.
    Chang CC; Liu YC; Cleveland RP; Perkins SL
    Am J Clin Pathol; 2000 Apr; 113(4):512-8. PubMed ID: 10761452
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
    Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
    Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
    Horn H; Ziepert M; Becher C; Barth TF; Bernd HW; Feller AC; Klapper W; Hummel M; Stein H; Hansmann ML; Schmelter C; Möller P; Cogliatti S; Pfreundschuh M; Schmitz N; Trümper L; Siebert R; Loeffler M; Rosenwald A; Ott G;
    Blood; 2013 Mar; 121(12):2253-63. PubMed ID: 23335369
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases.
    Tzankov A; Pehrs AC; Zimpfer A; Ascani S; Lugli A; Pileri S; Dirnhofer S
    J Clin Pathol; 2003 Oct; 56(10):747-52. PubMed ID: 14514777
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study.
    Kramer MH; Hermans J; Parker J; Krol AD; Kluin-Nelemans JC; Haak HL; van Groningen K; van Krieken JH; de Jong D; Kluin PM
    J Clin Oncol; 1996 Jul; 14(7):2131-8. PubMed ID: 8683246
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Investigation of expressions of PDK1, PLK1 and c-Myc in diffuse large B-cell lymphoma.
    Feng Y; Lin J; Liu Y; Tang Y; Zhou Y; Zhong M
    Int J Exp Pathol; 2019 Feb; 100(1):32-40. PubMed ID: 30912195
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
    Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F
    Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
    Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expression of ice, bcl-2, c-myc and p53 in different bone marrow cell populations from patients with diffuse large B-cell lymphoma.
    Madrigal-Velázquez M; Avilés A; Neri N; Huerta J; Martínez-Jaramillo G; Mayani H
    Leuk Lymphoma; 2006 Apr; 47(4):665-73. PubMed ID: 16690525
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rearrangements of bcl-1, bcl-2, bcl-6, and c-myc in diffuse large B-cell lymphomas.
    Kawasaki C; Ohshim K; Suzumiya J; Kanda M; Tsuchiya T; Tamura K; Kikuchi M
    Leuk Lymphoma; 2001; 42(5):1099-106. PubMed ID: 11697627
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Frequency of Double Expresser in Selected Cases of High Grade Diffuse Large B-Cell Lymphomas.
    Naseem M; Asif M; Khadim MT; Ud-Din H; Jamal S; Shoaib I
    Asian Pac J Cancer Prev; 2020 Apr; 21(4):1103-1107. PubMed ID: 32334477
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma.
    Frost M; Newell J; Lones MA; Tripp SR; Cairo MS; Perkins SL
    Am J Clin Pathol; 2004 Mar; 121(3):384-92. PubMed ID: 15023043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.